Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 May 27

PMID 37240564

Authors

Rafael S Rodriguez-Torres

David Uher

Emma L Gay

Giorgia Coratti

Sally Dunaway Young

Annemarie Rohwer

Robert Muni Lofra

Darryl C De Vivo

Michio Hirano

Nancy W Glynn

Jacqueline Montes

Affiliations

Soon will be listed here.

Abstract

Fatigue, a common symptom, together with the characteristic of performance fatigability, are well-documented features of SMA that impact quality of life and function. Importantly, establishing associations between multidimensional self-reported fatigue scales and patient performance has proven difficult. This review was conducted to evaluate the various patient-reported fatigue scales applied in SMA, with the objective of considering the limitations and advantages of each measure. Variable use of fatigue-related nomenclature, including conflicting terminology interpretation, has affected assessment of physical fatigue attributes, specifically perceived fatigability. This review encourages the development of original patient-reported scales to enable perceived fatigability assessment, providing a potential complementary method of evaluating treatment response.

Citing Articles

An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy.

Slayter J, Casey L, McCullum S, Drost D, Banks A, OConnell C J Rehabil Med. 2025; 57():jrm41254.

PMID: 39810476 PMC: 11748171. DOI: 10.2340/jrm.v57.41254.

Calculation of the Minimal Clinically Important Difference in Upper and Lower Limb Motor Assessment in Spinal Muscular Atrophy.

Hara T, Miyazaki Y, Shimizu-Motohashi Y, Nishida D, Kamimura A, Takeuchi M Prog Rehabil Med. 2025; 10():20250001.

PMID: 39781427 PMC: 11704608. DOI: 10.2490/prm.20250001.

The association between gait speed and falls in ambulatory adults with spinal muscular atrophy: a retrospective pilot study.

Jira K, Jaworek A, Allen M, Zhao S, Kelly K, Arnold W Front Neurol. 2024; 15:1491466.

PMID: 39697435 PMC: 11652354. DOI: 10.3389/fneur.2024.1491466.

Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study.

Crawford T, Day J, De Vivo D, Krueger J, Mercuri E, Nascimento A Front Neurol. 2024; 15:1419791.

PMID: 39105058 PMC: 11299114. DOI: 10.3389/fneur.2024.1419791.

Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study.

Yoon J, Jeong Y, Lee J, Lee D, Lee K, Shin Y BMC Neurol. 2024; 24(1):210.

PMID: 38902631 PMC: 11188501. DOI: 10.1186/s12883-024-03725-w.

References

Mentis G, Blivis D, Liu W, Drobac E, Crowder M, Kong L . Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron. 2011; 69(3):453-67. PMC: 3044334. DOI: 10.1016/j.neuron.2010.12.032. View

Friedman J, Brown R, Comella C, Garber C, Krupp L, Lou J . Fatigue in Parkinson's disease: a review. Mov Disord. 2006; 22(3):297-308. DOI: 10.1002/mds.21240. View

McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh W . A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017; 17(1):68. PMC: 5381033. DOI: 10.1186/s12883-017-0853-y. View

Enoka R, Duchateau J . Translating Fatigue to Human Performance. Med Sci Sports Exerc. 2016; 48(11):2228-2238. PMC: 5035715. DOI: 10.1249/MSS.0000000000000929. View

Errico F, Marino C, Grimaldi M, Nuzzo T, Bassareo V, Valsecchi V . Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy. Biomolecules. 2022; 12(10). PMC: 9599672. DOI: 10.3390/biom12101431. View

Mercuri E, Finkel R, Muntoni F, Wirth B, Montes J, Main M . Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018; 28(2):103-115. DOI: 10.1016/j.nmd.2017.11.005. View

Ripolone M, Ronchi D, Violano R, Vallejo D, Fagiolari G, Barca E . Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. JAMA Neurol. 2015; 72(6):666-75. PMC: 4944827. DOI: 10.1001/jamaneurol.2015.0178. View

Madruga-Garrido M, Vazquez-Costa J, Medina-Cantillo J, Branas M, Cattinari M, de Lemus M . Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study). Neurol Ther. 2021; 10(1):361-373. PMC: 8140031. DOI: 10.1007/s40120-020-00229-w. View

Enoka R, Almuklass A, Alenazy M, Alvarez E, Duchateau J . Distinguishing between Fatigue and Fatigability in Multiple Sclerosis. Neurorehabil Neural Repair. 2021; 35(11):960-973. DOI: 10.1177/15459683211046257. View

10.

Osmanovic A, Ranxha G, Kumpe M, Wurster C, Stolte B, Cordts I . Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Ther Adv Neurol Disord. 2021; 14:1756286421998902. PMC: 7940734. DOI: 10.1177/1756286421998902. View

11.

Gandevia S, Enoka R, McComas A, Stuart D, Thomas C . Neurobiology of muscle fatigue. Advances and issues. Adv Exp Med Biol. 1995; 384:515-25. DOI: 10.1007/978-1-4899-1016-5_39. View

12.

Falk K, Swedberg K, Gaston-Johansson F, Ekman I . Fatigue is a prevalent and severe symptom associated with uncertainty and sense of coherence in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2006; 6(2):99-104. DOI: 10.1016/j.ejcnurse.2006.05.004. View

13.

Billones R, Liwang J, Butler K, Graves L, Saligan L . Dissecting the fatigue experience: A scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions. Brain Behav Immun Health. 2021; 15:100266. PMC: 8474156. DOI: 10.1016/j.bbih.2021.100266. View

14.

Dangouloff T, Servais L . Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. Ther Clin Risk Manag. 2019; 15:1153-1161. PMC: 6778729. DOI: 10.2147/TCRM.S172291. View

15.

Gollie J, Patel S, Harris-Love M, Cohen S, Blackman M . Fatigability and the Role of Neuromuscular Impairments in Chronic Kidney Disease. Am J Nephrol. 2022; 53(4):253-263. PMC: 9871956. DOI: 10.1159/000523714. View

16.

Mercuri E, Darras B, Chiriboga C, Day J, Campbell C, Connolly A . Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018; 378(7):625-635. DOI: 10.1056/NEJMoa1710504. View

17.

Iannaccone S, Hynan L, Morton A, Buchanan R, Limbers C, Varni J . The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord. 2009; 19(12):805-12. PMC: 2796341. DOI: 10.1016/j.nmd.2009.09.009. View

18.

van der Heul A, van Eijk R, Wadman R, Asselman F, Cuppen I, Nievelstein R . Mastication in Patients with Spinal Muscular Atrophy Types 2 and 3 is Characterized by Abnormal Efficiency, Reduced Endurance, and Fatigue. Dysphagia. 2021; 37(4):715-723. PMC: 9345836. DOI: 10.1007/s00455-021-10351-y. View

19.

Robert R, Paxton R, Palla S, Yang G, Askins M, Joy S . Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory ™ generic core scales, cancer module, and multidimensional fatigue scale in long-term adult survivors of pediatric cancer. Pediatr Blood Cancer. 2012; 59(4):703-7. PMC: 3358502. DOI: 10.1002/pbc.24099. View

20.

Hjartarson H, Nathorst-Boos K, Sejersen T . Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. Drug Des Devel Ther. 2022; 16:1865-1883. PMC: 9208376. DOI: 10.2147/DDDT.S214174. View